dc.contributor.author | Jones, L | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Starling, N | |
dc.coverage.spatial | Netherlands | |
dc.date.accessioned | 2024-09-13T14:58:07Z | |
dc.date.available | 2024-09-13T14:58:07Z | |
dc.date.issued | 2024-09-01 | |
dc.identifier | ARTN 102789 | |
dc.identifier | S0305-7372(24)00117-8 | |
dc.identifier.citation | Cancer Treatment Reviews, 2024, 129 pp. 102789 - | en_US |
dc.identifier.issn | 0305-7372 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6394 | |
dc.identifier.eissn | 1532-1967 | |
dc.identifier.eissn | 1532-1967 | |
dc.identifier.doi | 10.1016/j.ctrv.2024.102789 | |
dc.identifier.doi | 10.1016/j.ctrv.2024.102789 | |
dc.description.abstract | Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is evolving. HER-2 is overexpressed in a portion of GI cancers and is an emerging target for therapy, with recent FDA tumor agnostic approval for trastuzumab deruxtecan. Testing for HER-2 expression is not standardized across GI cancers, methodology requires further optimization and standardization as HER-2 targeted therapy emerges into the treatment landscape. There is established rationale for use of HER-2 targeted therapy in first line treatment of metastatic gastric cancer, and emerging evidence with variable benefit in bile duct, pancreatic and colorectal cancers. | |
dc.format | Print-Electronic | |
dc.format.extent | 102789 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER SCI LTD | en_US |
dc.relation.ispartof | Cancer Treatment Reviews | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Biliary cancer | |
dc.subject | Colorectal cancer | |
dc.subject | Gastric cancer | |
dc.subject | Gastrointestinal cancer | |
dc.subject | HER-2 | |
dc.subject | Pancreatic cancer | |
dc.subject | Humans | |
dc.subject | Gastrointestinal Neoplasms | |
dc.subject | Receptor, ErbB-2 | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Trastuzumab | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.subject | Camptothecin | |
dc.subject | Immunoconjugates | |
dc.title | HER-2 directed therapies across gastrointestinal tract cancers - A new frontier. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-06-18 | |
dc.date.updated | 2024-09-13T14:54:24Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.ctrv.2024.102789 | en_US |
rioxxterms.licenseref.startdate | 2024-09-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38959629 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.ctrv.2024.102789 | |
pubs.volume | 129 | |
icr.researchteam | Medicine (RMH) | en_US |
dc.contributor.icrauthor | Cunningham, David | |
dc.contributor.icrauthor | Starling, Naureen | |
icr.provenance | Deposited by Mr Arek Surman on 2024-09-13. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0305737224001178-main.pdf | |